About Us

A bio-pharmaceutical enterprise specializing in the R&D,production and sales of human vaccines

       Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “OLYMVAX” or “the Company”) is a bio-pharmaceutical enterprise specializing in the R&D, production and sales of human vaccines. The Company was founded in 2009 with a registered capital of RMB 405,265,000 and was successfully listed on the SSE Science and Technology Innovation Board (Stock Code: 688319) on June 8, 2021. Since its establishment, the Company has been committed to providing consumers at home and abroad with safe, effective and high-quality human vaccine products, including the upgrade products of traditional vaccines developed to improve the quality of life of the people with broad market demand, and the innovative vaccine products with great future market potential, which are not yet met or urgently needed for disease control and prevention. Currently, it has been granted 62 Chinese invention patents, 2 US patents and 1 European patent.


The Company has implemented a dual-wheel drive strategy of leveraging the strengths of innovative vaccine development and traditional vaccine upgrading and a R&D strategy of laying equal stress on independent development and joint development.

R&D Center

Aim to become an “internationally renowned and domestically leading” vaccine supplier.

       The Company has a professional R&D team composed of senior researchers who are engaged in biological products for a long time in China. Furthermore, experts and consultants in the field of biological products at home and abroad are recruited to provide strong technical support and guidance for the establishment, implementation and concern resolution of R&D projects.